Skeletal Muscle-derived Cell Implantation for the Treatment of Fecal Incontinence: a Phase III, Randomized, Controlled, Double Blind, Two Armed Clinical Study
Latest Information Update: 14 Mar 2025
At a glance
- Drugs ICEF 15 (Primary)
- Indications Faecal incontinence
- Focus Registrational; Therapeutic Use
- Acronyms FI-3 Fidelia; Fidelia
- Sponsors Innovacell Biotechnologie GmbH
Most Recent Events
- 12 Mar 2025 Planned End Date changed from 31 Jul 2026 to 31 Jul 2027.
- 12 Mar 2025 Planned primary completion date changed from 31 Mar 2026 to 31 Mar 2027.
- 20 Nov 2023 Planned End Date changed from 31 Aug 2024 to 31 Jul 2026.